Clinical Trial Update: Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AMR101 (ethyl icosapentate) on triglyceride levels in patients with hypertriglyceridemia on statins; study completed and results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• AMR101 (ethyl icosapentate)

Snippet

Sponsor: Amarin Pharma Inc. | Conditions: Hypertriglyceridemia | Phase 3 | Status: COMPLETED | Results posted: 2022-04-25